Locally Advanced Rectal Cancer (LARC)
Conditions
Brief summary
Local recurrence (LR) in locally advanced rectal cancer (LARC) correlated with poor survival and impaired quality of life. The aim of this study was to develop and validate machine learning (ML) models integrating clinicopathological features and inflammatory signature to predict LR in LARC patients undergoing neoadjuvant therapy followed by total mesorectal excision.
Detailed description
To address the gap in accessible and integrative risk prediction, this study aimed to develop and validate an interpretable machine learning model for the early prediction of postoperative local recurrence in LARC patients using a multicenter cohort. We employed SHapley Additive exPlanations (SHAP) analysis to elucidate feature importance and provide clear interpretations for individual predictions, with the ultimate goal of evaluating the model's clinical utility in guiding personalized patient management-particularly by identifying high-risk patients in clinical practice and informing tailored follow-up and treatment strategies to improve patient outcomes.
Interventions
None listed
Sponsors
Cai Zerong
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosed cT\>=3 or cN+ stage rectal cancer by pelvic MRI or enhanced CT scan; 2. Pathological proved primary rectal adenocarcinoma; 3. Recieved full-cource radiation or more than 3 cycles of chemotherapy before surgery; 4. Recieved radical tumor resection by TME surgery.
Exclusion criteria
1. Diganosed with any distant metastasis disease or locally unresectable disease before neoadjuvant treatment or surgery; 2. Recieved local resection surgery (R2 resection) or postoperative pathology confirmed positive surgical margins (R1 resection); 3. Patients who died due to intra- or post-operative complications; 4. Patient who die or relapse within 30 days after surgery; 5. Patients who had a prior history of malignancy within 5 years before surgery; 6. Patients who were loss of follow-up or had inadequate clinical data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local recurrence | From date of randomization until the date of death from local recurrence, assessed up to 120 months | Local recurrence (LR) was defined as recurrent rectal cancer within the pelvic, including-but not limited to- lateral nodal recurrence, presacral recurrence, anastomotic recurrence, or perineal recurrence. |
Contacts
STUDY_DIRECTORZerong Cai, MD
Sixth Affiliated Hospital, Sun Yat-sen University
Outcome results
None listed